Insights On Drug Development

  1. From Lipids To Launch: End-To-End Therapy Development 8/20/2026

    Explore integrated capabilities spanning lipid manufacturing, nanoparticle formulation, and more with support designed to move complex therapies from preclinical development through commercialization.

  2. Targeted LNPs: From Ligand Conjugation To Process Optimization 8/20/2026

    Explore an integrated workflow for targeted lipid nanoparticle development, covering ligand conjugation, candidate screening, and scalable manufacturing for cell-specific nucleic acid delivery.

  3. Integrated QC As A Development Strategy: Reducing Late-Stage Analytical Risk 8/20/2026

    Learn how early QC integration, proactive analytical risk management, and cross-functional collaboration can improve validation readiness, reduce development surprises, strengthen release testing predictability, and help protect critical clinical manufacturing timelines.

  4. Accelerating Phase: Supply Without Sacrificing Discipline 8/20/2026

    Faster clinical supply delivery starts with the right strategy. Explore how planning, collaboration, communication, and quality systems keep programs on track.

  5. Oral Delivery Of PROTACs: Integrating Molecular Design And Enabling Formulation 8/20/2026

    Explore how integrated molecular design and formulation strategies can overcome the unique oral-delivery challenges of PROTACs, transforming complex degraders into viable, scalable medicines.

  6. Risk-Based Spray Drying Scale-Up: From Early Feasibility To Commercial Control Strategy 8/20/2026

    Discover how science, modeling, risk assessment, and DoE turn spray-dried dispersion scale-up from trial-and-error transfer into a predictable, robust path to commercial manufacturing.

  7. A Positive GMP Experience: Replacing Functional Handoffs With Project-Based Execution 8/20/2026

    Explore strategies for creating a stronger GMP culture through effective quality practices, collaboration, training, and continuous improvement. Learn how positive compliance experiences can support operational excellence, reduce risk, and strengthen manufacturing performance.

  8. Small-Scale Prototyping with Scale in Mind: Building Drug Product Robustness Earlier 8/20/2026

    Learn how intentional small-scale development workflows can reduce scale-up risk by improving process understanding, strengthening formulation robustness, identifying critical quality attributes early, and creating a more predictable path from prototype to clinical manufacturing.

  9. SEDDS: Improving Oral Bioavailability Of Poorly Soluble Compounds 8/20/2026

    Nearly 90% of marketed drugs have poor water solubility. Learn how self-emulsifying drug delivery systems (SEDDS) resolve oral bioavailability failures across BCS Class II and IV compounds.

  10. Curia's Approach To Regulatory Compliance In Japan 8/20/2026

    Japan's pharmaceutical market demands J-DMF registration, Foreign Manufacturer Accreditation, and GMP compliance. Learn how experienced CDMO support simplifies PMDA submissions and accelerates your market entry.